Joseph Catanzaro Analyst Performance

Analyst at Mizuho

Joseph Catanzaro is a stock analyst at Mizuho focused in the medical sector, covering 26 publicly traded companies. Over the past year, Joseph Catanzaro has issued 18 stock ratings, including buy and hold recommendations. While full access to Joseph Catanzaro's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joseph Catanzaro's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 78 Last 7 Years
Buy Recommendations: 77.33% 58 Buy Ratings
Companies Covered: 26 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	77.3%	58 ratings
Hold	22.7%	17 ratings
Sell	0.0%	0 ratings

Out of 75 total stock ratings issued by Joseph Catanzaro at Mizuho, the majority (77.3%) have been Buy recommendations, followed by 22.7% Hold.

Best & Worst Calls

Best Call
0000.0%
OCUL
Nov 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
FIGS
Aug 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	96.2% of companies on NASDAQ	25 companies
NYSE	3.8% of companies on NYSE	1 company

Joseph Catanzaro, an analyst at Mizuho, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 25 companies	96.2%
	Retail/Wholesale 1 company	3.8%

Joseph Catanzaro of Mizuho specializes in stock coverage within the Medical sector, with additional focus on Retail/Wholesale companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 15 companies	57.7%
PHARMACEUTICAL PREPARATIONS 3 companies	11.5%
MED - DRUGS 2 companies	7.7%
BIOTECHNOLOGY 2 companies	7.7%
MEDICAL INFO SYS 1 company	3.8%
RETAIL - APP/SHOE 1 company	3.8%
DIAGNOSTIC SUBSTANCES 1 company	3.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	3.8%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
RVMD Revolution Medicines	10/21/2025	Initiated Coverage	$54.01	$90.00	Outperform
NRIX Nurix Therapeutics	10/21/2025	Initiated Coverage	$10.39	$24.00	Outperform
KYMR Kymera Therapeutics	10/21/2025	Initiated Coverage	$60.50	$81.00	Outperform
CLDX Celldex Therapeutics	10/21/2025	Initiated Coverage	$27.67	$48.00	Outperform
APGE Apogee Therapeutics	10/21/2025	Initiated Coverage	$56.94	$105.00	Outperform
NRIX Nurix Therapeutics	10/10/2025	Lower Price Target	$10.86	$32.00	Overweight
IBRX ImmunityBio	5/20/2025	Upgrade	$2.80	$5.00	Overweight
CTMX CytomX Therapeutics	5/15/2025	Boost Price Target	$1.99	$5.00	Overweight
CTMX CytomX Therapeutics	4/14/2025	Initiated Coverage	$0.53	$2.50	Overweight
IOVA Iovance Biotherapeutics	2/28/2025	Lower Price Target	$5.26	$6.00	Neutral
SDGR Schrodinger	2/27/2025	Lower Price Target	$21.70	$45.00	Overweight
MRUS Merus	2/13/2025	Initiated Coverage	$40.26	$84.00	Overweight
GILD Gilead Sciences	2/12/2025	Boost Price Target	$103.45	$110.00	Overweight
EXEL Exelixis	2/12/2025	Boost Price Target	$34.91	$38.00	Overweight
IOVA Iovance Biotherapeutics	1/31/2025	Lower Price Target	$6.01	$7.50	Neutral
KROS Keros Therapeutics	1/17/2025	Lower Price Target	$11.09	$15.00	Overweight
EXEL Exelixis	1/13/2025	Boost Price Target	$35.09	$37.00	Overweight
HALO Halozyme Therapeutics	1/10/2025	Boost Price Target	$53.13	$53.00	Neutral

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.